<p>Ferulic acid, a natural active ingredient, mainly exerts antitumor activity by disrupting mitochondrial function and has the advantages of low toxicity and high efficiency. However, poor water solubility and low bioavailability have limited its further development. This article uses triphenylphosphonium salts (TPP<sup>+</sup>) with both amphiphilicity and tumor mitochondrial targeting to modify the structure of ferulic acid, and designs and synthesizes a series of TPP<sup>+</sup> conjugated ferulic acid derivatives. Compared with ferulic acid, the water solubility, mitochondrial targeting and antitumor activity of TPP-conjugated ferulic acid derivatives were significantly enhanced. Among them, compound <b>I</b><sub><b>4</b></sub> showed excellent anti-cervical cancer activity, mainly by reducing ATP synthesis and promoting ROS production, thus activating mitochondria-mediated apoptotic signaling to induce apoptosis in HeLa cells. <b>I</b><sub><b>4</b></sub> also inhibited HeLa cell migration and caused cell cycle arrest to the G0/G1 phase. In the mouse model, the effective therapeutic concentration of <b>I</b><sub><b>4</b></sub> was 2.5&#xa0;mg/kg and the LD<sub>50</sub> was 98.11&#xa0;mg/kg. <b>I</b><sub><b>4</b></sub> demonstrated similar anti-cervical cancer activity, a larger therapeutic window and a higher safety profile than with the first-line anticancer agent cisplatin.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Design, synthesis, and in vitro and in vivo anticancer activity of mitochondrial targeted ferulic acid derivatives

  • Yuyu Wu,
  • Ximeng Zhang,
  • Haocheng Li,
  • Xuelian Liu,
  • Jinyao Li

摘要

Ferulic acid, a natural active ingredient, mainly exerts antitumor activity by disrupting mitochondrial function and has the advantages of low toxicity and high efficiency. However, poor water solubility and low bioavailability have limited its further development. This article uses triphenylphosphonium salts (TPP+) with both amphiphilicity and tumor mitochondrial targeting to modify the structure of ferulic acid, and designs and synthesizes a series of TPP+ conjugated ferulic acid derivatives. Compared with ferulic acid, the water solubility, mitochondrial targeting and antitumor activity of TPP-conjugated ferulic acid derivatives were significantly enhanced. Among them, compound I4 showed excellent anti-cervical cancer activity, mainly by reducing ATP synthesis and promoting ROS production, thus activating mitochondria-mediated apoptotic signaling to induce apoptosis in HeLa cells. I4 also inhibited HeLa cell migration and caused cell cycle arrest to the G0/G1 phase. In the mouse model, the effective therapeutic concentration of I4 was 2.5 mg/kg and the LD50 was 98.11 mg/kg. I4 demonstrated similar anti-cervical cancer activity, a larger therapeutic window and a higher safety profile than with the first-line anticancer agent cisplatin.